BioLingus (Cayman) Limited (SUBL)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	222.25M
Revenue (ttm)	n/a
Net Income	-584,786
EPS	-0.05
Shares Out	11.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About SUBL

BioLingus in an exempted company with limited liability incorporated under the laws of the Cayman Islands, which is structured as a holding company whose main business operations are conducted through our subsidiaries in Switzerland and to a lesser extent, HK SAR, the People’s Republic of China and Australia. We are a biotechnology company spearheading the development of oral (specifically, sublingual) delivery of peptides and proteins. The main peptide used to improve the technology was exenatide, which was the first commercial glucagon-like p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: SUBL
• Website: https://www.biolingus.ch/

Financial Performance

Data Source: SEC filings Last updated: Aug 20, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error